Pipeline compound
VK2735
VK2735 is an investigational dual agonist of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, developed by Viking Therapeutics. It has no marketing authorisation in any territory. This profile summarises receptor mechanism and clinical-register status, with published statements reproduced as attributed quotations.
- Developer
- Viking Therapeutics
- Also known as
- VK-2735
Mechanism
GLP-1 and GIP are the two principal incretin hormones. Their receptors, GLP-1R and GIPR, are class B G-protein-coupled receptors that couple to Gs and adenylate cyclase, and both are expressed in pancreatic islets as well as in central and peripheral tissues. A dual agonist is a single molecule engineered to recruit both receptors rather than one.
VK2735 is described in the peer-reviewed literature as a GLP-1/GIP receptor dual agonist. Mechanistically it therefore sits in the same receptor pairing as tirzepatide, and in a different pairing from oxyntomodulin-based GLP-1/glucagon dual agonists such as mazdutide, or from triple agonists that add glucagon receptor activity.
Viking Therapeutics has reported development of both a subcutaneous and an oral formulation. Formulation route affects exposure and absorption characteristics; it does not change the receptor targets.
Clinical programme status
- Investigational. VK2735 is not approved in the United Kingdom, European Union or United States.
- Phase 2 subcutaneous data from the VENTURE study were published in the peer-reviewed journal Obesity in 2026.
- Viking Therapeutics has publicly described a Phase 3 programme (VANQUISH) for the subcutaneous formulation and continued Phase 2 work on the oral formulation. Registry entries are searchable on ClinicalTrials.gov.
Published statements, quoted
Reproduced verbatim from the sources named. Peptx makes no claim of its own on these points.
“This study aimed to determine doses of VK2735, a novel glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide (GLP-1/GIP) receptor dual agonist, that are effective for weight loss over 13 weeks of treatment.”
Not yet stocked
Register interest
VK2735 is not currently supplied by Peptx. Leave an email address and we will notify you once verified reference material is available. No purchase, no obligation, and the address is used for this notice only.
Frequently asked questions
- What is VK2735?
- VK2735 is an investigational dual agonist of the GLP-1 and GIP receptors developed by Viking Therapeutics, studied in both subcutaneous and oral formulations.
- How does VK2735 differ from mazdutide?
- VK2735 pairs GLP-1 receptor activity with GIP receptor activity. Mazdutide pairs GLP-1 receptor activity with glucagon receptor activity. They are different receptor combinations.
- Is VK2735 approved anywhere?
- No. It is an investigational compound with no marketing authorisation in the United Kingdom, European Union or United States.
- Does Peptx supply VK2735?
- No. VK2735 is not currently stocked. You can register an email address on this page to be notified if verified reference material becomes available.